Overview

Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder

Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
0
Participant gender:
All
Summary
To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Venlafaxine Hydrochloride
Criteria
Inclusion Criteria:

- Male or female outpatient

- 8-17 year old

- diagnosis of Social Anxiety Disorder

Exclusion Criteria:

- concomitant psychiatric or medical disorders which interfere with safety or assessment